Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
61
GTHP Quote, Financials, Valuation and Earnings
Last price:
$0.32
Seasonality move
:
-8.93%
Day range:
$0.31 - $0.32
52-week range:
$0.06 - $0.32
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
130.49x
P/B ratio:
--
Volume:
31.8K
Avg. volume:
8K
1-year change:
97.53%
Market cap:
$26.8M
Revenue:
$7K
EPS (TTM):
-$0.04
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Guided Therapeutics, Inc. has 34999900% upside to fair value with a price target of -- per share.
GTHP vs. S&P 500
-
Over the past 5 trading days, Guided Therapeutics, Inc. has overperformed the S&P 500 by 47.25% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Guided Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Guided Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Guided Therapeutics, Inc. reported revenues of $60K.
Earnings Growth
-
Guided Therapeutics, Inc. has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Guided Therapeutics, Inc. reported earnings per share of -$0.01.
Enterprise value:
30.7M
EV / Invested capital:
-9.51x
Price / LTM sales:
130.49x
EV / EBIT:
--
EV / Revenue:
172.48x
PEG ratio (5yr expected):
-0.07x
EV / Free cash flow:
-27.63x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$9K
Return On Assets:
-242.05%
Net Income Margin (TTM):
-1478.65%
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
-808.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $66K | $38K | $178K | -- | $60K | |
| Gross Profit | -$143.3K | -$73.1K | $9K | -$24K | $8K | |
| Operating Income | -$3.9M | -$2.1M | -$2.2M | -$561K | -$485K | |
| EBITDA | -$3.8M | -$2M | -$2.1M | -$537K | -$458K | |
| Diluted EPS | -$0.10 | -$0.04 | -$0.04 | -$0.01 | -$0.01 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.3M | $3.5M | $1.6M | $1M | $799K | |
| Total Assets | $1.7M | $3.9M | $1.9M | $1.2M | $903K | |
| Current Liabilities | $5.1M | $5.1M | $4.8M | $6M | $6.5M | |
| Total Liabilities | $6.8M | $6.5M | $5.5M | $6.2M | $6.5M | |
| Total Equity | -$5.1M | -$2.7M | -$3.7M | -$4.9M | -$5.6M | |
| Total Debt | $2.8M | $1.4M | $732K | $667K | $1.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$1.7M | -$1.1M | -$1.1M | -$473K | -$277K | |
| Cash From Investing | -$3K | -- | -$2K | -- | -$2K | |
| Cash From Financing | -$214K | $586K | $1M | $392K | $181K | |
| Free Cash Flow | -$1.8M | -$1.1M | -$1.1M | -$473K | -$279K | |
GTHP
Sector
Market Cap
$26.8M
$28.1M
Price % of 52-Week High
99.38%
51.42%
Dividend Yield
0%
0%
Shareholder Yield
-4.24%
-1.45%
1-Year Price Total Return
97.53%
-19.74%
Beta (5-Year)
0.639
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.26
200-day SMA
Buy
Level
$0.20
Bollinger Bands (100)
Buy
Level
0.22 - 0.28
Chaikin Money Flow
Buy
Level
542.3K
20-day SMA
Buy
Level
$0.25
Relative Strength Index (RSI14)
Buy
Level
64.42
ADX Line
Sell
Level
41.02
Williams %R
Sell
Level
0
50-day SMA
Buy
Level
$0.25
MACD (12, 26)
Buy
Level
0.01
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
103.6K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-164.3012)
Sell
CA Score
(Annual)
Level (-22.0992)
Buy
Beneish M-Score
(Annual)
Level (-4.0491)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (37.9558)
Sell
Piotroski F Score
(Annual)
Level (2)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (0)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Guided Therapeutics, Inc. is a medical technology company, which engages in developing medical devices. It also focuses on the selling and marketing of its LuViva advanced cervical scan non-invasive cervical cancer detection device. The company was founded by Shabbir Bakir Bambot and Mark L. Faupel in 1992 and is headquartered in Norcross, GA.
Stock Forecast FAQ
In the current month, GTHP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GTHP average analyst price target in the past 3 months is --.
-
Where Will Guided Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Guided Therapeutics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Guided Therapeutics, Inc.?
Analysts are divided on their view about Guided Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Guided Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Guided Therapeutics, Inc.'s Price Target?
The price target for Guided Therapeutics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GTHP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Guided Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of GTHP?
You can purchase shares of Guided Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Guided Therapeutics, Inc. shares.
-
What Is The Guided Therapeutics, Inc. Share Price Today?
Guided Therapeutics, Inc. was last trading at $0.32 per share. This represents the most recent stock quote for Guided Therapeutics, Inc.. Yesterday, Guided Therapeutics, Inc. closed at $0.32 per share.
-
How To Buy Guided Therapeutics, Inc. Stock Online?
In order to purchase Guided Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get GTHP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GTHP
Sector
P/E ratio
--
23.98x
PEG ratio
-0.07x
-0.01x
P/B ratio
--
1.81x
Price / LTM sales
130.49x
1.60x
Growth Metrics
GTHP
Sector
Revenue growth
-72.73%
4.62%
Earnings growth
20.66%
10.88%
Revenue (5-year growth)
-27.93%
6.5%
Earnings forecast
--
-$0.20
Profitability
GTHP
Sector
Profitability FY 2024
-$93K
$3.6M
Return on invested capital
--
-31.84%
Return on assets
-242.05%
-27.89%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
Dec
19
Next Earnings Date
Dec
19
Estimated Next Earnings Date
Mar
20
Balance Sheet
GTHP
Sector
Total cash
$87K
$26.6M
Short term investments
--
$25.7M
Total assets
$1.4M
$78M
Long term debt
$1.2M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 24.85% over the past day.
Sell
36
INSP alert for Dec 19
Inspire Medical Systems, Inc. [INSP] is down 19.66% over the past day.
Sell
40
INSM alert for Dec 19
Insmed, Inc. [INSM] is down 16.08% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
